Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MZR
|
|||
| Former ID |
DIB002471
|
|||
| Drug Name |
Bucelipase alfa
|
|||
| Synonyms |
Exinalda; Kiobrina; BSSL, Biovitrum; Bile salt stimulated lipase, Arexis; Bile salt stimulated lipase, Biovitrum; Bile salt stimulated lipase, PPL Therapeutics; HrBSSL, Biovitrum; Human recombinant bile salt stimulated lipase, Biovitrum; TgBSSL, PPL Therapeutics
Click to Show/Hide
|
|||
| Indication | Exocrine pancreatic insufficiency [ICD-11: DC35.1] | Phase 3 | [1] | |
| Company |
Astra Hassle AB
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bile-salt-activated lipase (CEL) | Target Info | Modulator | [2] |
| BioCyc | Triacylglycerol degradation | |||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01413581) Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.